Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.22 Average PT from Brokerages

Key Points

• Niagen Bioscience, Inc. has received an average "Buy" rating from five analysts, with a consensus 1-year price target of $13.22.
• The company reported earnings per share of $0.04 for the last quarter, exceeding estimates of $0.02, and achieved revenues of $31.12 million, above the anticipated $28.55 million.
• Institutional investors currently own 15.41% of Niagen Bioscience stock, with Prudential Financial Inc. significantly increasing its stake by 247.2% in the last quarter.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) has earned a consensus recommendation of "Buy" from the five analysts that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $13.42.

A number of research firms have commented on NAGE. HC Wainwright raised their price objective on Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Monday. Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group raised their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Finally, Roth Capital reiterated a "buy" rating and issued a $23.00 price target (up previously from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th.

Niagen Bioscience Trading Up 5.4%

NASDAQ:NAGE traded up $0.53 on Friday, hitting $10.26. The company's stock had a trading volume of 480,016 shares, compared to its average volume of 944,373. The stock has a fifty day moving average of $11.77 and a two-hundred day moving average of $8.30. The firm has a market capitalization of $818.24 million, a P/E ratio of 48.86 and a beta of 2.12. Niagen Bioscience has a one year low of $2.70 and a one year high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%. The company had revenue of $31.12 million for the quarter, compared to analyst estimates of $28.55 million.

Institutional Investors Weigh In On Niagen Bioscience

Several hedge funds have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new position in Niagen Bioscience during the 4th quarter worth about $1,154,000. State of Tennessee Department of Treasury acquired a new position in Niagen Bioscience during the 4th quarter worth about $140,000. XTX Topco Ltd acquired a new position in Niagen Bioscience during the 4th quarter worth about $120,000. Oxford Asset Management LLP acquired a new position in Niagen Bioscience during the 4th quarter worth about $151,000. Finally, Walleye Capital LLC acquired a new position in Niagen Bioscience during the 4th quarter worth about $215,000. Institutional investors and hedge funds own 15.41% of the company's stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.